IP Library Granted Patent US 7,357,891
Granted Patent B2
US 7,357,891 · App. 10/768,809 · Granted Apr 15, 2008

Process for making an ingestible film

Assignee: MonoSol Rx, LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,357,891
App. No.
10/768,809
Granted
Apr 15, 2008
Kind
B2
Abstract

The invention relates to film products containing desired levels of active components and methods of their preparation. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. Desirably, the films may be exposed to temperatures above that at which the active components typically degrade without concern for loss of the desired activity.

Claims (26)

1. A process for making an ingestible film having a substantially uniform distribution of components and a desired level of a pharmaceutical or biological active component, comprising the steps of:

(a) combining a polymer component, water and a pharmaceutical or biological active component to form a matrix with a uniform distribution of said components;

(b) forming a film from said matrix;

(c) providing a conveyor surface having top and bottom sides;

(d) feeding said film onto said top side of said surface; and

(e) drying said film within about 10 minutes or fewer by applying hot air currents to said bottom side of said conveyor surface with substantially no hot air currents on the top side of said surface and exposing said film to a temperature above a degradation temperature of said pharmaceutical or biological active component, wherein said degradation temperature is 70° C. or higher,

wherein said pharmaceutical or biological active component is maintained at said desired level.

2. The process of claim 1 , wherein said drying step maintains a non-self-aggregating uniform heterogeneity of said components throughout said film.

3. The process of claim 1 , wherein said film is flexible when dried.

4. The process of claim 1 , wherein said film is self-supporting.

5. The process of claim 1 , wherein uniform distribution determines the amount of active material component per area.

6. The process of claim 1 , wherein a specific amount of the active material component may be obtained from said film by cutting said film to a predetermined size.

7. A process for making an ingestible film having a substantially uniform distribution of components and a desired level of a pharmaceutical or biological active component, comprising the steps of:

(a) forming a masterbatch premix of a water-soluble polymer component and water;

(b) feeding a predetermined amount of said premix to at least one mixer;

(c) adding a pharmaceutical or biological active component to said at least one mixer;

(d) mixing said pharmaceutical or biological active component and said predetermined amount of said premix to form a matrix having a uniform distribution of components;

(e) forming a film from said matrix;

(f) providing a conveyor surface having top and bottom sides;

(g) feeding said film onto said top side of said surface; and

(h) drying said film by applying heat to said bottom side of said conveyor surface and exposing said film to a temperature above a degradation temperature of said pharmaceutical or biological active component, wherein said degradation temperature is 70° C. or higher,

wherein said drying step further comprises rapidly forming a visco-elastic film within about the first 4.0 minutes by applying hot air currents to said bottom side of said surface in the absence of hot air currents on the ton side of said surface; and

drying said visco-elastic film to form a self-supporting ingestible film,

wherein said pharmaceutical or biological active component is maintained at said desired level.

8. The process of claim 1 , wherein said drying of said film reduces the weight percent of said water to about 10% or less.

9. The process of claim 7 , wherein said drying of said film reduces the weight percent of said water to about 10% or less.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded May 13, 2026
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 075646/0258 →
SECURITY INTEREST Recorded Nov 2, 2023
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 065446/0494 →
RELEASE OF SECURITY INTEREST Recorded Nov 1, 2023
From: U.S. BANK TRUST COMPANY NATIONAL ASSOCIATION (AS SUCCESSOR IN INTEREST TO U.S BANK NATIONAL ASSOCIATION)
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 065426/0642 →
SECURITY INTEREST Recorded Jul 15, 2019
From: AQUESTIVE THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 049758/0082 →
RELEASE OF SECURITY INTEREST Recorded Jul 15, 2019
From: PERCEPTIVE CREDIT HOLDINGS, LP
To: AQUESTIVE THERAPEUTICS, INC.; MONOSOL RX, INC.; MSRX US, LLC
Reel/Frame 049757/0733 →
AMENDMENT TO PATENT SECURITY AGREEMENT RECORDED AT REEL/FRAME 039707/0194 Recorded Jan 30, 2018
From: AQUESTIVE THERAPEUTICS, INC.
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 045279/0802 →
CHANGE OF NAME Recorded Jan 29, 2018
From: MONOSOL RX, LLC
To: AQUESTIVE THERAPEUTICS, INC.
Reel/Frame 045196/0389 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2016
From: WHITE OAK GLOBAL ADVISORS, LLC
To: MONOSOL RX, LLC
Reel/Frame 039774/0782 →
SECURITY INTEREST Recorded Aug 16, 2016
From: MONOSOL RX, LLC; MONOSOL RX, INC.; MSRX US, LLC
To: PERCEPTIVE CREDIT HOLDINGS, LP
Reel/Frame 039707/0194 →
SECURITY AGREEMENT Recorded Dec 18, 2012
From: MONOSOL RX, LLC
To: WHITE OAK GLOBAL ADVISORS, LLC, AS AGENT
Reel/Frame 029490/0156 →
SECURITY INTEREST Recorded Apr 11, 2008
From: MONOSOL RX LLC
To: WHITE OAK GLOBAL ADVISORS, LLC, AS AGENT
Reel/Frame 020797/0799 →
CORRECTIVE ASSIGNMENT TO CORRECT THE THE NAME OF THE ASSIGNEE TO MONOSOL RX, LLC PREVIOUSLY RECORDED ON REEL 019002 FRAME 0496. ASSIGNOR(S) HEREBY CONFIRMS THE CORRECT SPELLING OF THE ASSIGNEE IS MONOSOL RX, LLC. Recorded Aug 15, 2007
From: KOSMOS PHARMA
To: MONOSOL RX, LLC
Reel/Frame 019695/0684 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2007
From: KOSMOS PHARMA
To: MONOSOLRX, LLC
Reel/Frame 019002/0496 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2004
From: YANG, ROBERT K.; FUISZ, RICHARD C.; MYERS, GARY L.; FUISZ, JOSEPH M.
To: MONOSOLRX LLC
Reel/Frame 017146/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2004
From: FUISZ, RICHARD C.; YANG, ROBERT K.; MYERS, GARY L.; FUISZ, JOSEPH M.
To: KOSMOS PHARMA
Reel/Frame 014952/0316 →
Continuity (11)
Continuation In Part PCTUS023257500 · Oct 11, 2002
Continuation In Part PCTUS023259400 · Oct 11, 2002
Continuation In Part PCTUS023254200 · Oct 11, 2002
Provisional Application 6032886800 · Oct 12, 2001
Provisional Application 6038693700 · Jun 7, 2002
Provisional Application 6041427600 · Sep 27, 2002
Provisional Application 6032886800 · Oct 12, 2001
Provisional Application 6038693700 · Jun 7, 2002
Provisional Application 6037194000 · Apr 11, 2002
Provisional Application 6044374100 · Jan 30, 2003
Related Publication 20040258896A1 · Dec 23, 2004